Treatment for primary liver cancer using PTS100 injections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of PTS100, administered as an intratumoral injection therapy, in patients with primary Hepatocellular Carcinoma (HCC) who are not eligible for surgery or local regional therapies. Participants will receive 30% of their total tumor volume in PTS100 through multiple injections, with the treatment adjusted based on individual tolerability. The treatment course continues until the total dose is completed, and efficacy will be assessed 28 days post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female, ≥ 20 years and ≤ 80 years of age.
* Patients with clinically confirmed primary HCC following American Association for the Study of Liver Diseases (AASLD, Appendix 1) guidance:

  1. Cyto-histological evidence, or
  2. Coincident imaging evidence using computerized tomography (CT) or magnetic resonance imaging (MRI)
* Based on investigator discretion, patients who are diagnosed at Barcelona Clinic Liver Cancer (BCLC) stage B and are ineffective or unsuitable for resection, immediate liver transplantation, Trans Arterial Chemoembolization (TACE), or current local ablative treatment and meet all of the following conditions at study entry:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
  2. Child Pugh score class A or B.
* Patients with at least one measurable lesion with size ≥ 1 cm.
* Patients with cumulative total treated tumor volume ≤ 366 cm3 and ≤ 4 target tumors.
* Patients with adequate bone marrow, liver and renal function within 28 days prior to study entry, as defined by the following:

  1. Hemoglobin \> 10.0 g/dl.
  2. Absolute neutrophil count (ANC) \> 1,500/mm3.
  3. Platelet count \> 80k/mm3 correctable by component therapy.
  4. Albumin ≥ 3 g/dl.
  5. Total bilirubin \< 2 mg/dL.
  6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 5 x upper normal limit (UNL).
  7. Blood urea nitrogen (BUN) and serum creatinine \< 1.5 x UNL.
  8. International normalized ratio (INR) \< 1.5 or prothrombin time (PT) \< 15 seconds.
* Patients with life expectancy \> 3 months as judged by investigator.
* Patients who understand and comply to the study procedure and be willing to provide a written informed consent form.

Exclusion Criteria:

* Infiltrative HCC or tumor burden ≥ 50% of liver parenchyma.
* Patients with cumulative total treated tumor volume \> 366 cm3 or more than 4 target tumors.
* Any target tumor exceeds 8.8 cm in diameter.
* The treated tumor is located in close proximity to another organ (e.g. gall bladder, liver capsule, diaphragm ) or major blood vessel and less than 0.5 cm in distance .
* Presence of metastasis or vascular invasion.
* Systemic chemotherapy treatment for HCC within 12 weeks prior to study entry.
* Major surgery within 4 weeks prior to study entry (e.g. thoracolaparotomy is not allowed, but noninvasive surgery, e.g. biopsy, is allowed).
* Use of any investigational drugs, biologics, or devices within 4 weeks prior to study entry or planned use during the course of study.
* Any other severe disease (e.g. active infection, uncontrolled diabetes mellitus, severe heart dysfunction or angina, gastric ulcer, active auto-immune disease) judged by the investigator to limit subject participation in the study.
* Female subjects who are pregnant or lactating. Women of childbearing potential must have a negative urine pregnancy test performed within seven days prior to the start of study drug and agree to practice medically acceptable contraceptive regimen from screening until at least 28 days after the study treatment. Patients who are postmenopausal for at least 1 year (\> 12 months since the last menstrual cycle) or were surgically sterilized do not require the pregnancy test.
* Known or suspected allergy and/or hypersensitivity to any of the ingredients of PTS100.
* Any target lesion blocked by bile ducts or important blood vessels, judged by investigator, that is difficult to conduct intratumoral injection.
* Any condition, judged by investigator, that shows subjects are not suitable for participation.

Where it's running

• Taipei Medical University Hospital
  Taipei City, Taiwan Recruiting
• Taipei Veterans General Hospital
  Taipei City, Taiwan Recruiting
• National Taiwan University Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Ja Der Liang — National Taiwan University Hospital
• Study coordinator: Ben Liu
• Email: ben.liu@gongwinbiopharm.com
• Phone: +886-2-2503-5282

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)

  This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.

  Recruiting AstraZeneca · Al Mansurah and 16 other locations · NCT07650773

• GLP-1 RA plus standard treatment in first-line metastatic GI cancers

  This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.

  Recruiting Early Phase 1 University of Arizona · Tucson, Arizona · NCT07627191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.